CA3074139A1 - Compounds and compositions for ire1 inhibition - Google Patents

Compounds and compositions for ire1 inhibition Download PDF

Info

Publication number
CA3074139A1
CA3074139A1 CA3074139A CA3074139A CA3074139A1 CA 3074139 A1 CA3074139 A1 CA 3074139A1 CA 3074139 A CA3074139 A CA 3074139A CA 3074139 A CA3074139 A CA 3074139A CA 3074139 A1 CA3074139 A1 CA 3074139A1
Authority
CA
Canada
Prior art keywords
amino
pyrazin
imidazo
naphthalen
methylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3074139A
Other languages
English (en)
French (fr)
Inventor
Richard M. Keenan
Bradley J. Backes
Dustin J. MALY
Charles Reynolds
Ben Whittaker
Jamie Knight
Jon Sutton
George Hynd
Feroz R. PAPA
Scott A. OAKES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Optikira LLC
Original Assignee
University of California San Diego UCSD
Optikira LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD, Optikira LLC filed Critical University of California San Diego UCSD
Publication of CA3074139A1 publication Critical patent/CA3074139A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3074139A 2017-09-01 2018-08-31 Compounds and compositions for ire1 inhibition Pending CA3074139A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553320P 2017-09-01 2017-09-01
US62/553,320 2017-09-01
PCT/US2018/049081 WO2019046711A2 (en) 2017-09-01 2018-08-31 COMPOUNDS AND COMPOSITIONS FOR INHIBITING IRE1

Publications (1)

Publication Number Publication Date
CA3074139A1 true CA3074139A1 (en) 2019-03-07

Family

ID=65526075

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3074139A Pending CA3074139A1 (en) 2017-09-01 2018-08-31 Compounds and compositions for ire1 inhibition

Country Status (13)

Country Link
US (1) US11649237B2 (https=)
EP (1) EP3675858B1 (https=)
JP (1) JP2020532589A (https=)
KR (1) KR20200066301A (https=)
CN (1) CN111526877B (https=)
AU (1) AU2018326721B2 (https=)
BR (1) BR112020004226A2 (https=)
CA (1) CA3074139A1 (https=)
IL (1) IL272845B2 (https=)
MX (1) MX2020002322A (https=)
SG (1) SG11202001609RA (https=)
WO (1) WO2019046711A2 (https=)
ZA (1) ZA202001320B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7444458B2 (ja) * 2018-09-21 2024-03-06 学校法人福岡大学 プリオン病治療薬
US20220194945A1 (en) * 2019-02-27 2022-06-23 Optikira, LLC Imidazolopyridine Compounds For IRE1 Inhibition
CN113795254B (zh) * 2019-02-27 2024-08-09 奥普提卡拉公司 用于ire1抑制的吡唑并吡啶化合物
CA3188602A1 (en) * 2020-08-07 2022-02-10 Richard Keenan Pyrazolopyridine compounds and methods of inhibiting ire1 using same
KR20230118855A (ko) * 2020-11-13 2023-08-14 더 리전츠 오브 더 유니버시티 오브 캘리포니아 IRE1α 억제제 및 이의 용도
EP4460492A1 (en) * 2022-01-07 2024-11-13 (INSERM) Institut National de la Santé et de la Recherche Médicale Compounds containing a hydroxyphenyl moiety and their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
US8980899B2 (en) * 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
EP2555768B1 (en) * 2010-04-05 2018-08-29 Fosun Orinove Pharmatech, Inc. Ire-1 inhibitors
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
MX2015003874A (es) * 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
CA3016161A1 (en) * 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
EP3548476A4 (en) 2016-12-02 2020-05-20 Quentis Therapeutics, Inc. SMALL MOLECULAR IRE1 INHIBITORS

Also Published As

Publication number Publication date
EP3675858A2 (en) 2020-07-08
EP3675858A4 (en) 2021-03-17
RU2020112425A (ru) 2021-10-04
MX2020002322A (es) 2020-10-05
AU2018326721A1 (en) 2020-03-12
CN111526877A (zh) 2020-08-11
RU2020112425A3 (https=) 2022-03-31
WO2019046711A3 (en) 2020-04-02
IL272845B2 (en) 2023-12-01
KR20200066301A (ko) 2020-06-09
US11649237B2 (en) 2023-05-16
BR112020004226A2 (pt) 2020-11-17
JP2020532589A (ja) 2020-11-12
ZA202001320B (en) 2023-10-25
CN111526877B (zh) 2023-08-25
IL272845A (en) 2020-04-30
EP3675858B1 (en) 2023-04-26
US20200354367A1 (en) 2020-11-12
SG11202001609RA (en) 2020-03-30
AU2018326721B2 (en) 2022-12-01
WO2019046711A2 (en) 2019-03-07
IL272845B1 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
AU2020341681B2 (en) RIP1 inhibitory compounds and methods for making and using the same
CN112601750B (zh) Ptpn11（shp2）抑制剂
EP3675858B1 (en) Imidazo[1,5-a]pyrazine compounds and compositions for ire1 inhibition
EP3781156A1 (en) Spirocyclic compounds
CA3016182A1 (en) Substituted indole mcl-1 inhibitors
AU2017226004A1 (en) Inhibitors of WDR5 protein-protein binding
AU2016382372B2 (en) Sulfonamide derivative and preparation method and use thereof
AU2018285131A1 (en) Heteroaromatic compounds as Vanin inhibitors
CA2753135A1 (fr) Derives de pyrazolo[1,5-.alpha.]-1,3,5-triazines, leur preparation et leur application en therapeutique
CA3005918A1 (en) Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
JP2019509272A (ja) 脊髄性筋萎縮症の治療のための併用療法
CA3005236C (en) Heterocyclic compounds for the inhibition and treatment of sphingosine-1-phosphate mediated diseases
CN111315734B (zh) 作为食欲素受体拮抗剂的经取代的2-氮杂双环[3.1.1]庚烷和2-氮杂双环[3.2.1]辛烷衍生物
BR112013017164B1 (pt) composto e composição farmacêutica
CN118159535A (zh) 小分子sting拮抗剂
WO2017073743A1 (ja) 三環性化合物
CA3181351A1 (en) Nampt modulators
CA3131388A1 (en) Pyrazolopyridine compounds for ire1 inhibition
WO2019156861A1 (en) [1,2,4]triazolo[4,3-a]pyrazin-8-one derivatives
RU2795572C2 (ru) Соединения и композиции для ингибирования ire1
CA3131386A1 (en) Imidazolopyrazine compounds for ire1 inhibition
KR20240046553A (ko) Sting 길항제로서의 소분자 우레아 유도체
WO2024040190A1 (en) Indane and coumaran derivatives as fast skeletal muscle myosin inhibitors
WO2025175141A1 (en) Fast skeletal muscle myosin inhibitors
CN121511243A (zh) 用于治疗癌症及炎性疾病的咪唑并[1,2-a]吡啶化合物及其制备所述化合物的方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230822

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240823

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240823

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240823

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241017

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250217

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260302